Home > News > Stem Cells in Acute Lymphoblastic Leukaemia
Haematological Malignancies, Leukaemia, Stem Cell Transplantation
Read Time: 2 mins

Stem Cells in Acute Lymphoblastic Leukaemia

Published Online: May 15th 2012 European Oncology & Haematology, 2012;8(3):196-200 DOI: https://doi.org/10.17925/EOH.2012.08.3.196
Authors: Alex Elder, Olaf Heidenreich, Josef Vormoor
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

There has been significant debate over the identity of cancer stem cell populations in acute lymphoblastic leukaemia (ALL), with different groups reporting seemingly contradictory results. The latest findings suggest that tumour-propagating capacity is found within a high percentage of ALL blasts and that these cells have diverse immunophenotypes, which suggests that ALL follows a stochastic cancer stem cell model – as opposed to a hierarchical model. Recent data add a layer of complexity to the tumour evolution process by showing that the leukaemia-propagating compartment consists of multiple genetically diverse subclones related by Darwinian-style evolutionary trees. Differences in the cell of origin may also affect tumour development. In this article, we discuss the applicability of cancer stem cell models to ALL in the context of these recent findings.

Keywords

Cancer stem cells, acute lymphoblastic leukaemia, clonal evolution, cell of origin

Article:

In the early 1990s, pioneering work from John Dick’s laboratory demonstrated that only a rare subset of malignant acute myeloid leukaemia (AML) cells could reconstitute the disease following successive xenotransplantations in mice.1 This work was possible due to critical advances in haematopoietic stem cell (HSC) isolation based on surface marker expression profiles,2 and provided the first experimental evidence for a concept that had been previously discussed for decades: the cancer stem cell (CSC). The CSC model contends that long-term tumour growth is driven by a population of cells with stem cell-like properties, resulting in the formation of tumours that are functionally and morphologically heterogeneous.

This heterogeneity can be explained by two CSC models. In the hierarchical model, CSCs are a biologically distinct subset of cells that both sustain the stem cell pool through self-renewal and give rise to progeny lacking extensive proliferative capacity. This model is analogous to the function of stem cells in normal tissue development. It follows from this that elimination of the CSC compartment will result in cessation of tumour growth. In contrast, the stochastic model contends that all cells within a tumour have the potential to act as CSCs and that functional heterogeneity is influenced by other factors. These could be either intrinsic (e.g., varying levels of particular transcription factors) or extrinsic (e.g., the tumour niche).

There is a substantial amount of evidence that the hierarchicalmodel applies in some tumours. The initial findings of John Dick’s laboratory, which have since been expanded upon,3 showed that the long-term tumour-maintaining capacity in AML lies only within a rare subpopulation. Although other studies suggest the phenotype of these cells may be more diverse than initially thought,4,5 the bulk of the evidence indicates that AML follows a hierarchical stem cell model. Xenotransplantation studies have also demonstrated that other solid tumours follow the hierarchical model, including breast,6 colon7,8 and brain9 cancers. However, it appears that the model may not apply to all tumours, as the frequency of propagating cells in melanoma is very high (one in four)10 and stem cell activity is associated with all cellular phenotypes11 – although contradictory findings have been reported.12

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Correspondence

Josef Vormoor, Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Sir James Spence Institute, 4th floor, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK. E: h.j.vormoor@ncl.ac.uk

Received

2012-05-02T00:00:00

References

  1. Lapidot T, Sirard C, Vormoor J, et al., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice, Nature, 1994;367:645–8.
  2. Spangrude GJ, Heimfeld S, Weissman IL, Purification and characterization of mouse hematopoietic stem cells, Science, 1988;241:58–62.
  3. Hope KJ, Jin L, Dick JE, Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity, Nat Immunol, 2004;5:738–43.
  4. Goardon N, Marchi E, Atzberger A, et al., Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia, Cancer Cell, 2011;19:138–52.
  5. Taussig DC, Vargaftig J, Miraki-Moud F, et al., Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction, Blood, 2010;115:1976–84.
  6. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al., Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci U S A, 2003;100:3983–8.
  7. O’Brien CA, Pollett A, Gallinger S, Dick JE, A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, Nature, 2007;445:106–10.
  8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al., Identification and expansion of human colon-cancer-initiating cells, Nature, 2007;445:111–5.
  9. Singh SK, Clarke ID, Terasaki M, et al., Identification of a cancer stem cell in human brain tumors, Cancer Res, 2003;63:5821–8.
  10. Quintana E, Shackleton M, Sabel MS, et al., Efficient tumour formation by single human melanoma cells, Nature, 2008;456:593–8.
  11. Quintana E, Shackleton M, Foster HR, et al., Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized, Cancer Cell, 2010;18:510–23.
  12. Boiko AD, Razorenova OV, van de Rijn M, et al., Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271, Nature, 2010;466:133–7.
  13. Pui CH, Robison LL, Look AT, Acute lymphoblastic leukaemia, Lancet, 2008;371:1030–43.
  14. Kamel-Reid S, Letarte M, Sirard C, et al., A model of human acute lymphoblastic leukemia in immune-deficient SCID mice, Science, 1989;246:1597–600.
  15. Cox CV, Evely RS, Oakhill A, et al., Characterization of acute lymphoblastic leukemia progenitor cells, Blood, 2004;104:2919–25.
  16. Cobaleda C, Gutiérrez-Cianca N, Pérez-Losada J, et al., A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia, Blood, 2000;95:1007–13.
  17. Hong D, Gupta R, Ancliff P, et al., Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia, Science, 2008;319:336–9.
  18. Cox CV, Diamanti P, Evely RS, et al., Expression of CD133 on leukemia-initiating cells in childhood ALL, Blood, 2009;113:3287–96.
  19. Cox CV, Martin HM, Kearns PR, et al., Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia, Blood, 2007;109:674–82.
  20. Gerby B, Clappier E, Armstrong F, et al., Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations, Leukemia, 2011;25:1249–58.
  21. Le Viseur C, Hotfilder M, Bomken S, et al., In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties, Cancer Cell, 2008;14:47–58.
  22. Vormoor HJ, Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited, Cell Cycle, 2009;8:996–9.
  23. Hotfilder M, Röttgers S, Rosemann A, et al., Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal, Blood, 2002;100:640–6.
  24. Kong Y, Yoshida S, Saito Y, et al., CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL, Leukemia, 2008;22:1207–13.
  25. Morisot S, Wayne AS, Bohana-Kashtan O, et al., High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias, Leukemia, 2010;24:1859–66.
  26. Schmitz M, Breithaupt P, Scheidegger N, et al., Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment, Blood, 2011;118:1854–64.
  27. Rehe K, Wilson K, Bomken S, et al., unpublished data, 2012.
  28. Ishizawa K, Rasheed ZA, Karisch R, et al., Tumor-initiating cells are rare in many human tumors, Cell Stem Cell, 2010;7:279–82.
  29. Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al., Anti- CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells, Blood, 2008;112:568–75.
  30. Taussig DC, Pearce DJ, Simpson C, et al., Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia, Blood, 2005;106:4086–92.
  31. Uckun FM, Sather HN, Waurzyniak BJ, et al., Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children’s Cancer Group Study, Leuk Lymphoma, 1998;30:503–14.
  32. Wunderlich M, Chou FS, Link KA, et al., AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3, Leukemia, 2010;24:1785–8.
  33. Anderson K, Lutz C, van Delft FW, et al., Genetic variegation of clonal architecture and propagating cells in leukaemia, Nature, 2011;469:356–61.
  34. Notta F, Mullighan CG, Wang JC, et al., Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells, Nature, 2011;469:362–7.
  35. Waanders E, Scheijen B, van der Meer LT, et al., The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution, PLoS Genet, 2012;8:e1002533.
  36. Mullighan CG, Phillips LA, Su X, et al., Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia, Science, 2008;322:1377–80.
  37. Kuster L, Grausenburger R, Fuka G, et al., ETV6/RUNX1- positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling, Blood, 2011;117:2658–67.
  38. Van Delft FW, Horsley S, Colman S, et al., Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia, Blood, 2011;117:6247–54.
  39. Clappier E, Gerby B, Sigaux F, et al., Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse, J Exp Med, 2011;208:653–61.
  40. Gerrits A, Dykstra B, Kalmykowa OJ, et al., Cellular barcoding tool for clonal analysis in the hematopoietic system, Blood, 2010;115:2610–8.
  41. Barker N, Ridgway RA, van Es JH, et al., Crypt stem cells as the cells-of-origin of intestinal cancer, Nature, 2009;457:608–11.
  42. Jamieson CH, Chronic myeloid leukemia stem cells, Hematology Am Soc Hematol Educ Program, 2008:436–42.
  43. Kikushige Y, Ishikawa F, Miyamoto T, et al., Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia, Cancer Cell, 2011;20:246–59.
  44. Luckey CJ, Bhattacharya D, Goldrath AW, et al., Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells, Proc Natl Acad Sci U S A, 2006;103:3304–9.
  45. Cobaleda C, Jochum W, Busslinger M, Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors, Nature, 2007;449:473–7.
  46. Deshpande AJ, Cusan M, Rawat VP, et al., Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10- positive leukemia, Cancer Cell, 2006;10:363–74.
  47. Rossi M, Camera A, Barone M, et al., CD7(+) acute leukemia switching from a lymphoid to a myeloid phenotype, Haematologica, 2001;86:877.
  48. Dorantes-Acosta E, Arreguin-Gonzalez F, Rodriguez-Osorio CA, et al., Acute myelogenous leukemia switch lineage upon relapse to acute lymphoblastic leukemia: a case report, Cases J, 2009;2:154.
  49. Bellido M, Martino R, Aventín A, et al., Leukemic relapse as T-acute lymphoblastic leukemia in a patient with acute myeloid leukemia and a minor T-cell clone at diagnosis, Haematologica, 2000;85:1083–6.
  50. Castor A, Nilsson L, Astrand-Grundström I, et al., Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia, Nat Med, 2005;11:630–7.
  51. Barabé F, Kennedy JA, Hope KJ, et al., Modeling the initiation and progression of human acute leukemia in mice, Science, 2007;316:600–4.
  52. McCormack MP, Young LF, Vasudevan S, et al., The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal, Science, 2010;327:879–83.
  53. Berquam-Vrieze KE, Nannapaneni K, Brett BT, et al., Cell of origin strongly influences genetic selection in a mouse model of T-ALL, Blood, 2011;118:4646–56.
  54. Kamel-Reid S, Letarte M, Doedens M, et al., Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice, Blood, 1991;78:2973–81.
  55. Meyer LH, Eckhoff SM, Queudeville M, et al., Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways, Cancer Cell, 2011;19:206–17.
  56. Druker BJ, Perspectives on the development of a molecularly targeted agent, Cancer Cell, 2002;1:31–6.
  57. Hamilton A, Helgason GV, Schemionek M, et al., Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival, Blood, 2012;119:1501–10.
  58. Eppert K, Takenaka K, Lechman ER, et al., Stem cell gene expression programs influence clinical outcome in human leukemia, Nat Med, 2011;17:1086–93.
  59. Zhang J, Ding L, Holmfeldt L, et al., The genetic basis of early T-cell precursor acute lymphoblastic leukaemia, Nature, 2012;481:157–63.

Further Resources

Share this Article
Related Content In Stem Cell Transplantation
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72